Buying big into biotech: scale, financing, and the industrial dynamics of UK biotech, 1980-2009

This article explores how the UK's biotech firms have evolved in response to their financial environment. As investors' expectations about the potential of biotech have changed, funding options have opened up and closed down, leading firms to develop new business models and routes of technology development. After a favorable period, new constraints on stock market funding have forced UK biotech firms to compress their life cycles, constraining their ability to generate the late-stage drug candidates sought by large pharmaceutical firms. These changes are analyzed within a neo-Chandlerian framework in the context of a selection environment where rather than firms of varying inefficiencies being selected by an efficient market, we find entrepreneurs submitting themselves to an inefficient investment-selection process at the intersection of industries attempting to achieve their own scale economies. The article highlights the importance of the scale of investment at the firm and industry level, and suggests that decline in the size of the industry can have adverse consequences for investment and firm performance in this setting. Copyright 2013 The Author 2013. Published by Oxford University Press on behalf of Associazione ICC. All rights reserved., Oxford University Press.

[1]  I. Reid.  Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients , 2013, British Journal of Psychiatry.

[2]  Michael M. Hopkins,et al.  Big Pharma, little science? A bibliometric perspective on big pharma's R&D decline , 2013, ArXiv.

[3]  M. Mazzucato,et al.  The Entrepreneurial State , 2013 .

[4]  Roger M. Stein,et al.  Commercializing biomedical research through securitization techniques , 2012, Nature Biotechnology.

[5]  Ben Goldacre,et al.  Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients , 2012 .

[6]  Paul Nightingale,et al.  Servant Firms in Drug Discovery: a Neglected Project Based Organizational Form , 2012 .

[7]  J. Scannell,et al.  Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.

[8]  M. Hopkins.  Exploring funding routes for therapeutics firms , 2012 .

[9]  M. O'Neill,et al.  A biotech manager's handbook , 2012 .

[10]  M. Murray.  Business development: to the deal and beyond , 2012 .

[11]  A. Haldane,et al.  The Short Long , 2012 .

[12]  Michael M. Hopkins,et al.  The bioscience sector: challenges and opportunities , 2012 .

[13]  Michael O’Neill,et al.  Managing projects and portfolios in R&D: why and how , 2012 .

[14]  W. Lazonick,et al.  US Biopharmaceutical Finance and the Sustainability of the Biotech Business Model , 2011 .

[15]  John Hodgson,et al.  Public biotech 2010—the numbers , 2011, Nature Biotechnology.

[16]  Bruce L. Booth,et al.  In defense of life sciences venture investing , 2011, Nature Biotechnology.

[17]  Bernard H. Munos,et al.  How to Revive Breakthrough Innovation in the Pharmaceutical Industry , 2011, Science Translational Medicine.

[18]  F. Pammolli,et al.  The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.

[19]  K. Asadullah,et al.  Crowd sourcing in drug discovery , 2011, Nature Reviews Drug Discovery.

[20]  Josh Siepel.  Capabilities, policy and institutions in the emergence of venture capital in the UK and US , 2011 .

[21]  Michael M. Hopkins,et al.  Projects, Project Capabilities and Project Organizations , 2011 .

[22]  C. Haslam,et al.  Bio-pharma: A financialized business model , 2010 .

[23]  John Hodgson,et al.  Public biotech 2009—the numbers , 2010, Nature Biotechnology.

[24]  J. May,et al.  Wrong numbers? , 2010, Nature Biotechnology.

[25]  Nelson Phillips,et al.  Technology and Organization: Essays in Honour of Joan Woodward , 2010 .

[26]  Frank T. Rothaermel,et al.  Leveraging internal and external experience: exploration, exploitation, and R&D project performance , 2010 .

[27]  D. Haber,et al.  Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents , 2010, Nature Reviews Cancer.

[28]  Robert Kneller,et al.  The importance of new companies for drug discovery: origins of a decade of new drugs , 2010, Nature Reviews Drug Discovery.

[29]  B. Munos.  Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.

[30]  Irving Kirsch,et al.  The Emperor's New Drugs: Exploding the Antidepressant Myth , 2009 .

[31]  J. Lerner,et al.  Boulevard of Broken Dreams: Why Public Efforts to Boost Entrepreneurship and Venture Capital Have Failed--And What to Do about It , 2009 .

[32]  Bruce L. Booth.  Beyond the biotech IPO: a brave new world , 2009, Nature Biotechnology.

[33]  L. Lerer.  Venture capital and the European biotechnology industry , 2009 .

[34]  William Bains,et al.  Wasting cash—the decline of the British biotech sector , 2009, Nature Biotechnology.

[35]  Michael M. Hopkins,et al.  On a Critical Path: Genomics, the Crisis of Pharmaceutical Productivity and the Search for Sustainability , 2009 .

[36]  Bethan Hughes,et al.  Harnessing open innovation , 2009, Nature Reviews Drug Discovery.

[37]  Sarah Kaplan,et al.  Entrepreneurship and the Construction of Value in Biotechnology , 2008 .

[38]  J. Garnier,et al.  Rebuilding the R&D engine in big pharma. , 2008, Harvard business review.

[39]  Werner Reinartz,et al.  Cómo vender servicios rentablemente , 2008 .

[40]  Michael M. Hopkins,et al.  Sectoral Innovation Systems in Europe: Monitoring, Analysing Trends and Identifying Challenges in Biotechnology , 2008 .

[41]  Gordon Murray,et al.  Venture Capital and Government Policy , 2007 .

[42]  Markku V. J. Maula,et al.  Profit distribution and compensation structures in publicly and privately funded hybrid venture capital funds , 2007 .

[43]  J. DiMasi,et al.  The cost of biopharmaceutical R&D: is biotech different? , 2007 .

[44]  Charles Baden-Fuller,et al.  Shareholder returns and the exploration–exploitation dilemma: R&D announcements by biotechnology firms , 2007 .

[45]  Paul Nightingale,et al.  The myth of the biotech revolution: An assessment of technological, clinical and organisational change , 2007 .

[46]  Salih Zeki Ozdemir,et al.  Vertical alliance networks: The case of university–biotechnology–pharmaceutical alliance chains , 2007 .

[47]  N. Brown,et al.  Commercial development of stem cell technology: lessons from the past, strategies for the future. , 2006, Regenerative medicine.

[48]  W. Bains.  What you give is what you get: Investment in European biotechnology , 2006 .

[49]  W. Powell,et al.  Network Dynamics and Field Evolution: The Growth of Interorganizational Collaboration in the Life Sciences1 , 2005, American Journal of Sociology.

[50]  P. Danzon,et al.  Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances , 2003, Journal of health economics.

[51]  B. Bührlen,et al.  Human tissue-engineered products: Potential socio-economic impacts of a new European regulatory framework for authorisation, supervision and vigilance , 2005 .

[52]  Paul Nightingale,et al.  The myth of the biotech revolution. , 2004, Trends in biotechnology.

[53]  Gavin Cassar.  The Financing of Business Start-Ups , 2004 .

[54]  Andrew D. Henderson,et al.  Selection-Based Learning: The Coevolution of Internal and External Selection in High-Velocity Environments , 2004 .

[55]  Richard N. Langlois,et al.  Chandler in a Larger Frame: Markets, Transaction Costs, and Organizational Form in History , 2004, Enterprise & Society.

[56]  K. Meyer.  Knowledge and competitive advantage, the coevolution of firms, technology and national institutions , 2004 .

[57]  James Kalamas,et al.  The optimum time for drug licensing , 2003, Nature Reviews Drug Discovery.

[58]  Jeremy L. Hall,et al.  Capacity utilization revisited: software, control and the growth of large technical systems , 2003 .

[59]  Maurizio Zollo,et al.  Deliberate Learning and the Evolution of Dynamic Capabilities , 2002 .

[60]  Nile W. Hatch,et al.  As Time Goes By: From the Industrial Revolutions to the Information Revolution , 2002 .

[61]  Massimo Riccaboni,et al.  Technological Regimes and the Growth of Networks: An Empirical Analysis , 2001 .

[62]  R. Langlois.  The Vanishing Hand: The Changing Dynamics of Industrial Capitalism , 2001 .

[63]  F. Rothaermel.  Strategic Management Journal Research Note Incumbent's Advantage through Exploiting Complementary Assets via Interfirm Cooperation , 2022 .

[64]  F. Pammolli,et al.  Technological Regimes and the Growth of Networks , 2001 .

[65]  Paul Nightingale,et al.  The product-process-organisation relationship in complex development projects , 2000 .

[66]  Paul Nightingale,et al.  Economies of Scale in Experimentation: Knowledge and Technology in Pharmaceutical R&D , 2000 .

[67]  Constance E. Helfat,et al.  Product Sequencing: Co-Evolution of Knowledge, Capabilities and Products. , 2000 .

[68]  Gordon Murray,et al.  Early-stage venture capital funds, scale economies and public support , 1999 .

[69]  A. Ainamo,et al.  The Coevolution of New Organizational Forms in the Fashion Industry: a Historical and Comparative Study of France, Italy, and the United States , 1999 .

[70]  Henk W. Volberda,et al.  Where Do New Organizational Forms Come From? Management Logics as a Source of Coevolution , 1999 .

[71]  M. Sharp,et al.  European biotechnology: learning and catching-up. , 1999 .

[72]  Gordon Murray,et al.  Why has the investment performance of technology-specialist, European venture capital funds been so poor? , 1998 .

[73]  W. Powell.  Learning from Collaboration: Knowledge and Networks in the Biotechnology and Pharmaceutical Industries , 1998 .

[74]  Harry J. Sapienza,et al.  Venture capitalist governance and value added in four countries , 1996 .

[75]  W. Powell,et al.  Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology. , 1996 .

[76]  David J. Teece,et al.  The Dynamics of Industrial Capitalism: Perspectives on Alfred Chandler's Scale and Scope , 1993 .

[77]  N. Lamoreaux,et al.  Business Organization and the Myth of the Market Economy by William Lazonick (review) , 1992, Technology and Culture.

[78]  Philip R. Reilly.  Gene Dreams: Wall Street, Academia, and the Rise of Biotechnology , 1991 .

[79]  Luigi Orsenigo,et al.  The Emergence of Biotechnology: Institutions and Markets in Industrial Innovation , 1989 .

[80]  Luigi Orsenigo,et al.  The emergence of biotechnology , 1989 .

[81]  E. Hall,et al.  The nature of biotechnology. , 1988, Journal of biomedical engineering.

[82]  M. Dibner.  Biotechnology in Europe , 1986, Science.

[83]  Martin Kenney,et al.  Schumpeterian innovation and entrepreneurs in capitalism: A case study of the U.S. biotechnology industry , 1986 .

[84]  M. Weber,et al.  General Economic History , 1955, The Journal of Economic History.

[85]  John Maurice Clark,et al.  Studies in the economics of overhead costs , 1924 .

[86]  C. Babbage.  Economy of Machinery and Manufactures , 1832 .